ALFA Filings
Every announcement, straight from the exchange
Every Aurobindo Pharma business update announcement on NSE and BSE, newest first, each with its own page.
Time
5 announcements with these filters
Aurobindo Pharma received USFDA final approval for Perampanel Tablets in multiple strengths. The product will be manufactured by its subsidiary and launched in Q3FY27.
Aurobindo Pharma announced that the US FDA inspection of its subsidiary Apitoria Pharma's Unit-IV concluded with zero observations. This signals continued regulatory compliance for the facility.
Aurobindo Pharma reported the completion of a US FDA inspection at its subsidiary, Lannett Company LLC, which resulted in four procedural observations.
Aurobindo Pharma's subsidiary, Eugia Pharma Specialities Ltd., received a US FDA Warning Letter for its Unit I manufacturing facility. The unit contributes approximately 2% to group revenue.
Aurobindo Pharma has submitted its Business Responsibility & Sustainability Report for the financial year 2025-26 to the stock exchanges.